ArticleMolecular cancer2008
An integrative model for recurrence in ovarian cancer.
Article in Molecular cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- ACSM3 suppresses the pathogenesis of high-grade serous ovarian carcinoma via promoting AMPK activity.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Negative Regulation of the IL-1 System by IL-1R2 and IL-1R8: Relevance in Pathophysiology and Disease.Frontiers in immunology · 2022Review
- IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15-Dependent BMI1 Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Association between IL-1R2 polymorphisms and lung cancer risk in the Chinese Han population: A case-control study.Molecular genetics & genomic medicine · 2019Article
- Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.Immunological reviews · 2018Review
- Cytokine decoy and scavenger receptors as key regulators of immunity and inflammation.Cytokine · 2016Article
- Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.Integrative cancer therapies · 2016Article
- Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Acta biochimica et biophysica Sinica · 2016Review
- The double face of Morgana in tumorigenesis.Oncotarget · 2015Review
- Entropic analysis reveals a connection between the recurrence of cancer and chemotherapy.Saudi journal of biological sciences · 2015Article
- Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.The Journal of biological chemistry · 2015Article
- Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells.Medical oncology (Northwood, London, England) · 2015Article
- Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention.Molecular cancer · 2014Review
- Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy.Cancers · 2014Article
- Article
- Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.International journal of molecular sciences · 2013Article
- Decoys and Regulatory "Receptors" of the IL-1/Toll-Like Receptor Superfamily.Frontiers in immunology · 2013Article
- Linking epithelial-to-mesenchymal-transition and epigenetic modifications.Seminars in cancer biology · 2012Review
- Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.Journal of ovarian research · 2012Article
- Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association.Cancer research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.